The therapeutic mechanism of GGD for CHD may be related to steroid hormone biosynthesis metabolism, arachidonic acid metabolism, linoleic acid metabolism, PI3K-Akt signaling pathway, lipid and atherosclerosis, IL-17 signaling pathway, and relaxin signaling pathway. This evidence concerns the gene AKT1 and coronary artery disorder.